Vericiguat
- Generic Name
- Vericiguat
- Brand Names
- Verquvo
- Drug Type
- Small Molecule
- Chemical Formula
- C19H16F2N8O2
- CAS Number
- 1350653-20-1
- Unique Ingredient Identifier
- LV66ADM269
- Background
Vericiguat is a direct stimulator of soluble guanylate cyclase (sGC) used in the management of systolic heart failure to reduce mortality and hospitalizations. A key component of the NO-sGC-cGMP signaling pathway that helps to regulate the cardiovascular system, sGC enzymes are intracellular enzymes found in vascular smooth muscle cells (amongst other cell t...
- Indication
适用于近期心力衰竭失代偿经静脉治疗后病情稳定的射血分数降低（射血分数<45%）的症状性慢性心力衰竭成人患者，以降低发生心力衰竭住院或需要急诊静脉利尿剂治疗的风险。
- Associated Conditions
- Cardiovascular Mortality, Heart Failure Hospitalization
- Associated Therapies
- -
The CardioMEMS Vericiguat Heart Failure Trial
- Conditions
- Interventions
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Finn Gustafsson
- Target Recruit Count
- 17
- Registration Number
- NCT06671990
COgnitioN With VERiciGuat Evaluation in Heart Failure
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 120
- Registration Number
- NCT06601465
- Locations
- 🇨🇦
University of Calgary, Calgary, Alberta, Canada
🇨🇦University of Ottawa, Ottawa, Ontario, Canada
🇨🇦McGill University Health Center, Montreal, Quebec, Canada
The Impact of Vericiguat on Microvascular Function in Patients With Documented Vasospastic Angina Pectoris
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-05-16
- Target Recruit Count
- 55
- Registration Number
- NCT06415227
Effect of Vericiguat on Endpoint Events in Acute Coronary Syndrome( ACS）Patients With Ejection Fraction <45%
- Conditions
- Interventions
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2024-03-20
- Target Recruit Count
- 100
- Registration Number
- NCT06321094
- Locations
- 🇨🇳
the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Randomised Controlled Trial of Vericiguat in Patients With Coronary Microvascular Dysfunction Causing Stable Chest Pain (V-COM)
- Conditions
- Interventions
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 94
- Registration Number
- NCT06239974
- Locations
- 🇭🇰
The University of Hong Kong, Hong Kong, Hong Kong
SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery
- Conditions
- Interventions
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 170
- Registration Number
- NCT05812755
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT05806138
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 45
- Registration Number
- NCT05711719
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
Impact of Vericiguat on Hemodynamics of Heart Failure
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 30
- Registration Number
- NCT05704478
The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation
- Conditions
- Interventions
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Josef Stehlik
- Target Recruit Count
- 26
- Registration Number
- NCT05420012
- Locations
- 🇺🇸
Veterans Affairs Salt Lake City Health Care System (VAMC), Salt Lake City, Utah, United States
🇺🇸University of Utah Hospital, Salt Lake City, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.